EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC 3.0

Endoscopic findings of immune checkpoint inhibitor-related gastrointestinal adverse events

Min Kyu Kim, Sung Wook Hwang

Clinical Endoscopy · 30.11.2024 · 57 (6) · 725-734

DOI: 10.5946/ce.2024.003 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Clinical Endoscopy, erschienen am 30.11.2024. Verfasst von Min Kyu Kim und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0). Gefördert von: Korean Gastroenterology Fund for Future Development, Asan Institute for Life Sciences, Asan Medical Center.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The use of immune checkpoint inhibitors (ICIs) for the treatment of various malignancies is increasing. Immune-related adverse events can occur after ICI administration, with gastrointestinal adverse events constituting a significant proportion of these events. When ICI-related diarrhea/colitis is suspected, endoscopic evaluation is recommended to differentiate it from other etiologies and assess the severity of colitis. The distribution of intestinal inflammation in ICI-related colitis demonstrates a high frequency of extensive colitis (23–86%). However, isolated right-sided colitis (3–8%) and ileitis (2–16%) are less prevalent. Endoscopic findings vary and predominantly encompass features indicative of inflammatory bowel disease, including aphthae, ulcers, diffuse or patchy erythema, mucosal edema, loss of vascular pattern, and friability. The presence of ulcers and extensive intestinal inflammation are associated with a reduced response to treatment. Microscopic inflammation can be observed even in endoscopically normal mucosa, underscoring the need for biopsies of seemingly normal mucosa. Histological findings present with acute/chronic inflammation and occasionally exhibit characteristics observed in inflammatory bowel disease, microscopic colitis, or ischemic colitis. The first-line therapeutic choice for ICI-related diarrhea/colitis with a common terminology criteria for adverse events grade of 2 or above is corticosteroids, whereas infliximab and vedolizumab are recommended for refractory cases.

Schlagwörter

Stichwörter der Autor:innen

Drug-related side effects and adverse reactionsEndoscopy, gastrointestinalHistologyImmune checkpoint inhibitors

Autor:innen und Institutionen

  • Department of Gastroenterology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
  • Inflammatory Bowel Disease Center, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.

Förderung

  • Korean Gastroenterology Fund for Future Development
  • Asan Institute for Life Sciences, Asan Medical Center

Zitieren

APA

Kim, M. K., & Hwang, S. W. (2024). Endoscopic findings of immune checkpoint inhibitor-related gastrointestinal adverse events. Clinical Endoscopy, 57(6), 725-734. https://doi.org/10.5946/ce.2024.003

Vancouver

Kim MK, Hwang SW. Endoscopic findings of immune checkpoint inhibitor-related gastrointestinal adverse events. Clinical Endoscopy. 2024;57(6):725-734. doi:10.5946/ce.2024.003

BibTeX
@article{Kim2024,
  author = {Kim, Min Kyu and Hwang, Sung Wook},
  title = {Endoscopic findings of immune checkpoint inhibitor-related gastrointestinal adverse events},
  journal = {Clinical Endoscopy},
  year = {2024},
  volume = {57},
  number = {6},
  pages = {725--734},
  doi = {10.5946/ce.2024.003}
}
Kostenlos starten →